LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse.

@article{Quinet2009LXRLL,
  title={LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse.},
  author={Elaine M. Quinet and Michael D Basso and Anita R. Halpern and David W. Yates and Robert J Steffan and Valerie Clerin and Christine Resmini and J. S. Keith and Thomas J Berrodin and Irene Feingold and Wenyan Zhong and Helen B Hartman and Mark J. Evans and Stephen J. Gardell and Elizabeth A. DiBlasio-Smith and William M Mounts and Edward R Lavallie and Jay Wrobel and P. Azhahia Nambi and George P. Vlasuk},
  journal={Journal of lipid research},
  year={2009},
  volume={50 12},
  pages={2358-70}
}
Liver X receptors (LXRs) are ligand-activated transcription factors that coordinate regulation of gene expression involved in several cellular functions but most notably cholesterol homeostasis encompassing cholesterol transport, catabolism, and absorption. WAY-252623 (LXR-623) is a highly selective and orally bioavailable synthetic modulator of LXR, which demonstrated efficacy for reducing lesion progression in the murine LDLR(-/-) atherosclerosis model with no associated increase in hepatic… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

Nuclear receptors and their selective pharmacologic modulators.

Pharmacological reviews • 2013
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…